On Jul. 1, 2020, in a Perspective for the New England Journal of Medicine, members of the NIHﾒs Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Vaccines Working Group assessed practical considerations and prerequisites for using controlled human infection models, which can be used for human challenge studies, to support SARS-CoV-2 vaccine development.